Tag
In a large, diverse cohort of women with endometrial cancer, 11.9% harbored pathogenic germline variants, including Lynch syndrome and homologous recombination deficiency-related mutations. Testing at diagnosis identified most Lynch syndrom
The OPAL phase 2 trial compared neoadjuvant niraparib to standard platinum-taxane chemotherapy in newly diagnosed HR-deficient advanced ovarian cancer, showing inferior response rates with niraparib and a safety profile consistent with PARP
This article reviews real-world data supporting homologous recombination deficiency (HRD) testing in BRCA1/2 wild-type high-grade serous carcinoma and examines MYC amplification as a promising surrogate biomarker to guide PARP inhibitor the
In a 298-patient endometrial cancer cohort, HRR gene alterations were rare, enriched in aggressive tumor subsets, but did not predict survival or platinum sensitivity beyond integrated molecular classification.
